TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported ...

The genetic testing results also inform patients’ family members about their cancer risks so they can be proactive in screening and prevention. For now, GENETECA™ is only available to people with ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Germline editing is banned in most countries ... and scientists mostly find them through large genome-wide screenings followed by vigorously testing in cells and animals. These results unveil helpful ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...